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Very long-term follow-upAbstract Background: Preoperative short-term radiotherapy (PRT) in combination with
total mesorectal excision (TME) has shown to improve local control in rectal cancer treat-
ment, however without a survival beneﬁt and at the cost of increased morbidity. The current
study investigates the long-term health-related quality of life (HRQL) of patients 14 years
after treatment in the Dutch TME trial.
Methods: In the TME trial (1996–1999) 1530 Dutch patients with rectal cancer were treated
with TME and randomly assigned to PRT (5  5 Gy). In 2012 HRQL was evaluated in
surviving patients (n = 606) using a questionnaire combining EORTC QLQ-C30, EORTC
QLQ-CR29 and additional questions.
Findings: Results were obtained from 478 patients (82%), with a median follow up of 14 years.
PRT + TME patients without stoma reported more faecal leakage and higher stool frequency,
resulting in increased need of pads. Furthermore, irradiated males reported more erection
problems. However, radiotherapy did not have negative effects on overall functioning. Com-
pared with Dutch population, patients in both treatment arms reported a small decrease in
overall functioning and males reported less sexual activity, interest and enjoyment and moreLeiden,
L.M. Wiltink et al. / European Journal of Cancer 50 (2014) 2390–2398 2391erection difﬁculties. Irradiated females reported more vaginal dryness and more pain at inter-
course compared with Dutch population.
Interpretation: Long-term HRQL evaluation shows that treatment-related symptoms are still
present 14 years after treatment for rectal cancer. Radiotherapy increased bowel dysfunction
in patients without stoma. Compared with the Dutch population, both groups reported
increased sexual dysfunction. Despite these treatment-related symptoms, there was no differ-
ence in overall functioning and global health between TME and PRT + TME.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Local recurrence used to be a major problem in rectal
cancer treatment. With the introduction of total meso-
rectal excision (TME) over the last decades an improved
local control and survival has been achieved [1]. Several
randomised trials found an additional beneﬁt in local
control after preoperative radiotherapy (PRT) [2–4].
The Dutch TME trial was one of these trials in which
1861 patients were randomly allocated between short-
term preoperative radiotherapy followed by TME sur-
gery or TME alone. Local recurrence after TME was
11% at 10 years, compared to 5% after PRT + TME.
Despite this improvement in local control, there was
no beneﬁt in overall survival (TME: 49%, PRT + TME:
48% at 10 years) and PRT was associated with increased
treatment-related morbidity [5,6].
Due to the growing number of long-term rectal can-
cer survivors, together with the increased life expec-
tancy, long-term treatment-related morbidity and its
eﬀects on health-related quality of life (HRQL) have
become an important issue. Previous studies found that
at 5 years after treatment, irradiated rectal cancer
patients developed more bowel and sexual dysfunction
compared with non-irradiated patients [6–8]. Few stud-
ies investigated HRQL of rectal cancer survivors with
longer follow-up. More bowel dysfunction and hospital
admissions for bowel obstruction in irradiated patients
have been reported up to 10 years after diagnosis [9–
12]. The aim of this analysis was to evaluate the very
long-term HRQL of patients treated in the Dutch
TME trial still alive more than 12 years after diagnosis.
2. Patients and methods
2.1. Study population and treatment
From January 1996 until December 1999, 1861
patients with resectable rectal cancer were randomly
assigned to PRT followed by standardised TME surgery
or TME alone in a large, international, multicentre trial.
Patients were eligible if they had clinically resectable
rectal adenocarcinoma without evidence of distant
metastases.
The inferior margin of the tumour had to be located
below the level of S1/S2 and not further than 15 cm fromthe anal verge. In order to participate in the trial all
patients had to give informed consent before randomisa-
tion. The design of the trial is approved by the ethics com-
mittee and has been reported in previous studies [2,6].
Both radiotherapy and surgical procedures have been
reported in detail previously as well [2,6]. For radiother-
apy, patients were treated with a total dose of 25 Gy in
ﬁve fractions over 5–7 days delivered with a three or
four-ﬁeld technique. The clinical target volume included
the primary tumour and the mesentery containing the
perirectal, presacral and internal iliac nodes up to the
S1/S2 junction. If an abdominoperineal resection
(APR) was planned, the perineum was included in the
clinical target volume, otherwise the lower ﬁeld border
was 3 cm above the anal verge. All patients underwent
surgery according to the TME principles [2,6].
HRQL was evaluated in all surviving Dutch patients
of the TME trial. To check the survival status of the
patients, information provided by the Central Bureau
of Genealogy and by patients’ general practitioners
was used. In July 2012 HRQL questionnaires were sent
to all surviving patients, except for patients who had
declined participation in the last questionnaire sent in
the TME trial. Patients who did not respond initially
were sent one reminder.
2.2. Measurements
The HRQL questionnaire was composed of the can-
cer speciﬁc European Organization for Research and
Treatment of Cancer (EORTC) core questionnaire
(EORTC QLQ-C30) [13] and the colorectal module
(EORTC QLQ-CR29) [14]. Because only a few ques-
tions about sexuality are included in the EORTC
QLQ-CR29, sexuality items from the previous colorectal
module (EORTC-CR38) [15] and items from prostate
(EORTC QLQ-PR25) [16] and cervical cancer (EORTC
QLQ-CX24) [17] modules were included. For most ques-
tions four-point Likert-type scales were used. All indi-
vidual-item responses and subscales were linearly
converted to 0–100 scales. Higher scores for functioning
represent a better level of functioning. For the symptom
items, a higher score reﬂects a higher level of symptoms
and therefore decreased HRQL.
In 2003 late morbidity of surviving Dutch patients of
the TME trial was assessed using a questionnaire that
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urinary function, impact of bowel and urinary dysfunc-
tion, and level of satisfaction with bowel, stoma and
urinary function. Questions were also asked about pain
in the back, buttock, legs and hips, stiﬀness of the hip,
walking diﬃculties, the use of walking aids and co
morbidities [6]. In order to acquire more detailed
information these additional questions were included in
the current questionnaire and scores were transformed
into binary outcome measures (i.e., only ‘no’ was no,
all other scores were considered as yes).2.3. Statistics
All data were analysed with IBM SPSS Statistics, ver-
sion 20.0. To compare characteristics between the treat-
ment groups the independent t test was used for
continuous variables and the x2 test for categorical vari-
ables. HRQL analysis and handling of missing values
were done according to the guidelines provided by the
EORTC Quality of Life Group [18]. Mean scores of
the treatment groups were compared using the Mann–
Whitney U test. For categorical items the x2 test was
used. Data from the Dutch norm population [19] were
matched for age and gender and compared with both
treatment groups by a linear regression model. Norm
data were available for the EORTC QLQ-C30 and for
questions about sexuality [19].
All patients who provided information about sexual
symptoms were included in the sexual analyses. To
guard against false-positive results due to multiple test-
ing, a two-sided P value of .01 was considered statisti-
cally signiﬁcant. Diﬀerences in mean scores were
interpreted as clinically relevant but small, if the diﬀer-
ences were between ﬁve and 10 points on a scale ofFig. 1. CONSORT diagr100 points. A diﬀerence between 10 and 20 points was
indicated as moderate and a diﬀerence greater than 20
points was interpreted as large [20].2.4. Role of the funding source
The funding sources did not have any role in the data
collection, analysis, interpretation or writing of the
manuscript.3. Results
3.1. Study population and compliance
Of 1530 Dutch study patients, 606 were still alive in
July 2012. Nineteen patients refused further participa-
tion on a previous questionnaire in 2003 and four
patients were untraceable, leaving 583 patients who were
sent a HRQL questionnaire (Fig. 1).
Of these, 478 returned the questionnaire, resulting in
a response rate of 82%. Among the responders, one
TME patient received chemo radiation and one TME
patient received postoperative 30 Gy instead of
50.4 Gy, and 10 TME patients received post- operative
chemotherapy. In the PRT + TME group, 14 patients
received a total dose less than 25 Gy, and 11 patients
received additional chemotherapy. The median follow-
up time since surgery was 14 years for the responders,
and 15 years for the non-responders (range 12–17 years).
Patient characteristics are equally balanced between
responders and non-responders (table 1).
Overall, the treatment groups did not diﬀer signiﬁ-
cantly with regard to questionnaire response rates and
missing items. Questionnaires were complete for all items
of the EORTC QLQ-C30 in 82.2% of the responders,am of study patients.
Table 1
Patient characteristics for the HRQL responders and non-responders.
Characteristics Responders P Non-responders P
PRT + TME (n = 241) TME (n = 237) (n = 105)
No. of patients % No. of patients % No. of patients %
Age, years .04 .57
Median 77 74 75
Range 43–95 39–93 42–97
Sex .12 .34
Male 150 62.2 131 55.3 67 63.8
Female 91 37.8 106 44.7 38 36.2
TNM stage .29 .76
0 6 2.5 9 3.8 3 2.9
I 104 43.1 95 40.1 46 43.8
II 64 26.6 68 28.7 25 23.8
III 64 26.6 65 27.4 31 29.5
IV 3 1.2 0 0 0 0
Distance to anal verge, cm* .71 .91
0–5 70 29.2 76 32.2 34 32.4
05–10 97 40.4 95 40.3 40 38.1
10–15 73 30.4 65 27.5 31 29.5
Operation type .48 .43
LAR 158 65.6 164 69.2 72 68.6
APR 74 30.7 68 28.7 27 25.7
Hartmann 9 3.7 5 2.1 5 4.8
Other 0 0 0 0 1 1.0
Stoma present .34 .09
Yes 107 44.4 95 40.1 35 33.3
No 134 55.6 142 59.9 70 66.6
Abbreviations: HRQL, health-related quality of life; PRT, preoperative short-term radiotherapy; TME, total mesorectal excision; LAR, low
anterior resection; APR, abdominoperineal resection.
Diﬀerence between treatment arms.
 Diﬀerence between responders and non-responders.
* For one irradiated patient and one non-irradiated patient, tumour location could not be determined.
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items and in 59.8% for all questions used in the 2003
HRQL analysis. When allowing up to two missing
items, these rates were 95.1%, 92.4%, and 84.6% respec-
tively. Sexually active women (29.9%) completed all sex-
ual items in 84.7%, and sexually active men (40.9%)
completed all sexual items in 91.3%. Non-irradiated
patients were slightly younger than irradiated patients
(median age 74 years in TME versus 77 years in
PRT + TME; P = .04), but all other patient characteris-
tics were well balanced between the treatment arms
(Table 1).3.2. Patient functioning
No signiﬁcant diﬀerences in mean scores of EORTC
QLQ-C30 functioning scales and global health status
were found between the treatment arms. However, com-
pared with the Dutch population both treatment groups
reported lower mean scores for emotional, cognitive,
and social functioning. All diﬀerences were small in
terms of clinical relevance. The PRT + TME patients
also reported a small decrease in physical functioningcompared with the Dutch population (diﬀerence 5.9
points, P < .001; table 2 and Fig. 2A).
3.3. Symptoms
While there were no diﬀerences in bowel symptoms
between treatment groups in patients with a stoma,
more PRT + TME patients without stoma had an
increase in stool frequency (mean PRT + TME 26.3 ver-
sus TME 19.4); this diﬀerence is mainly explained by
more PRT + TME patients reporting the response
option a little (during the day, PRT + TME 41.4% ver-
sus TME 28.6%). Furthermore, TME patients had less
faecal leakage (72.6% not at all after TME compared
to 54.3% after PRT + TME, Table 3) and less urge for
defecation, less defecation within 1 h of the last bowel
opening, and less anal mucus loss, leading to lower fre-
quency of use of pads for faecal leakage (Table 4). No
signiﬁcant diﬀerences were found in urinary function
between the treatment arms (Table 4). Furthermore,
no diﬀerences were reported in pain in the back, but-
tock, legs and hips, and in use of walking aids between
the treatment arms. However, a trend was shown
towards an increase in walking diﬃculties after
Table 2
Patient functioning scores and symptom scores of EORTC QLQ-C30.
Mean score PRT ± TME Mean score TME P* D PRT ± TME  Norm P D TME  Norm P
Global health status 77.2 78.5 .16 1.4 .29 2.6 .05
Functional scales
Physical functioning 77.5 80.9 .08 5.9 <.001 2.9 .01
Role functioning 79.4 81.4 .30 4.1 .01 2.5 .14
Emotional functioning 86.1 85.8 .35 3.5 .006 3.3 .009
Cognitive functioning 83.3 84.0 .33 5.7 <.001 5.1 <.001
Social functioning 86.8 87.7 .59 5.2 <.001 4.4 <.001
Symptom items
Fatigue 24.9 23.1 .62 5.8 <.001 3.8 .01
Nausea and vomiting 2.7 2.3 .83 .4 .65 0 .91
Pain symptoms 13.1 12.4 .43 7 <.001 7.6 <.001
Dyspnoea 14.1 14.3 .78 3.5 0.01 3.6 .008
Insomnia 18.1 23.6 .03 1.6 .35 6.3 <.001
Appetite loss 6.8 5.5 .44 2.9 .005 1.5 .15
Constipation 10.8 13.4 .43 3.9 .001 6.6 <.001
Diarrhoea 11 10.6 .89 6.9 <.001 6.7 <.001
Financial diﬃculties 5.5 4.9 .66 2.1 .04 1.5 .13
Higher scores for functioning indicate better functioning. For the symptom items, a higher score reﬂects a higher level of symptoms and decreased
HRQL. A negative diﬀerence in functioning indicates worse functioning in the treatment arms and a positive diﬀerence for symptoms indicates a
higher level of symptoms in the treatment arms compared to Norm.
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision; Norm, age and gender matched Dutch population.
* Diﬀerence between PRT + TME and TME.
 Diﬀerence between PRT + TME and Norm.
 Diﬀerence between TME and Norm.
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40.5% after TME, P = .02). Compared with the Dutch
population, diﬀerences in mean scores of EORTC
QLQ-C30 symptoms were found. Patients in both treat-
ment arms indicated more fatigue, dyspnoea, insomnia,
appetite loss, constipation, and diarrhoea, while indicat-
ing less pain. However, all these diﬀerences were small in
terms of clinical relevance (Table 2, Fig. 2B and C).
3.4. Sexual functioning
Of all males, 40.9% reported to be sexually active. A
signiﬁcant increase was found in erection diﬃculties in
the irradiated group (50.5% very much after
PRT + TME compared to 29.8% very much after
TME). Compared with the Dutch population, both
males treated with PRT + TME or TME alone reported
signiﬁcantly less interest in sex, less sexual activity, less
enjoyment of sex, and more erection diﬃculties: the dif-
ference in erection diﬃculties is large, whereas the diﬀer-
ence in sexual interest is moderate in terms of clinical
relevance (Table 5, Fig. 2D and E).
Of all females, 29.9% reported to be sexually active.
Irradiated females reported a trend towards more pain
during intercourse (7.5% quite a bit and 12.5% very
much after PRT + TME compared to 0% and 5.4%
respectively after TME), and decreased extent to which
sex was enjoyable. Compared with the Dutch popula-
tion, irradiated females reported a signiﬁcant, clinically
large diﬀerence in enjoyment of sex and pain during
intercourse, and a clinically moderate diﬀerence invaginal dryness, whereas this was not found in non-
irradiated females. In addition, irradiated females reported
a clinically large decrease in extent of enjoyment of sex,
and non-irradiated females a small decrease compared
with the Dutch population (Table 5, Fig. 2D and E).4. Discussion
This analysis of patient-reported HRQL in the Dutch
TME trial shows that treatment-related symptoms are
still present at 14 years after treatment for rectal cancer,
while overall patient functioning and global health are
similar between the treatment groups. After
PRT + TME, patients without stoma reported increased
bowel dysfunction compared with TME. Compared
with the Dutch population, both treatment groups
reported increased sexual dysfunction and a small
decrease in quality of life.
Our results provide unique information about the
very long-term HRQL of patients treated for rectal can-
cer using validated questionnaires with a high response
rate (82%). To our knowledge, only one study reported
HRQL of rectal cancer survivors after more than
10 years [12] and three observational studies reported
long-term anorectal and colorectal function after
10 years [9,21,22]. However, patients included in these
studies did not undergo surgery according to the TME
technique and in two studies patients underwent postop-
erative radiotherapy instead of preoperative radiother-
apy [21,22]. Moreover, HRQL of both treatment arms
Fig. 2. Mean scores of treatment arms compared to the mean scores of the Dutch population. Abbreviations: PRT, preoperative short-term
radiotherapy; TME, total mesorectal excision; Norm, age and gender matched Dutch population. Higher scores for functioning indicate better
functioning. For the symptom items, a higher score reﬂects a higher level of symptoms and decreased HRQL.
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Dutch population data.
Our present ﬁndings are consistent with the previous
reported ﬁndings of increased bowel dysfunction after
PRT + TME at 2 and 5 years after treatment in this trial
[6,23]. The data are also in line with other studies that
reported long-term bowel dysfunction [9,10]. In a study
that included 340 patients of the Eindhoven Cancer
Registry up to 10 years after treatment, more gastroin-
testinal and defecation problems (EORTC QLQ-
CR38) were found after PRT + TME compared with
patients who only underwent surgery [11]. In the Stock-
holm trials patients underwent surgery and PRT or sur-
gery alone, and HRQL of 139 rectal cancer survivors
was assessed 15 years after treatment. In the Stockholmtrials, patients who underwent PRT and anterior resec-
tion, reported more faecal incontinence compared to
the surgery only patients (57.1% after PRT + surgery
versus 26.2% after surgery alone) [12]. Bowel dysfunc-
tion can be caused by diﬀerent mechanisms. First, mus-
cles of the pelvic ﬂoor can be impaired by ﬁbrosis caused
by radiotherapy, resulting in a weaker pelvic ﬂoor and a
weakening of the anal sphincter and therefore in more
faecal leakage. Second, the myenteric plexus in the inter-
nal anal sphincter can be damaged due to PRT, which
impairs impulse conduction in sacral and pudendal
nerves [9]. The combination of the muscle and nerve
impairment is suggested to cause a stiﬀer and smaller
neorectum after radiotherapy [24], which can lead to a
higher pressure in the neorectum even when just small
Table 3
Scores of EORTC QLQ-CR29.
Mean score
PRT + TME
Mean score
TME
P
Body image 86.8 86.9 .87
Anxiety 84.1 80.4 .07
Weight 88.4 86.4 .17
Urinary frequency 29.9 28.4 .51
Urinary incontinence 14.6 12.8 .62
Dysuria 1.6 1.3 .39
Blood and mucus in stool 2.6 3.1 .57
Abdominal pain 5.2 6.6 .58
Buttock pain 10.7 6.8 .03
Bloating 8.5 11.8 .04
Dry mouth 17 19.7 .05
Hair loss 2.7 3 .83
Taste 4.8 4.3 .16
Patients with stoma
Stool frequency 13.1 11.6 .67
Flatulence 21.6 18.8 .31
Faecal leakage 15.1 10 .08
Sore skin 12.3 8.7 .20
Embarrassment 9.6 11.2 .54
Stoma care problems 3.9 2.2 .17
Patients without stoma
Stool frequency 26.3 19.4 .006
Flatulence 31.8 33.8 .43
Sore skin 22.5 10.1 <.001
Embarrassment 12.8 6.1 .04
Care problems 26.2 19 .09
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total
mesorectal excision.
Table 4
Urinary function and bowel function assessment.
PRT + TME
(%)
TME
(%)
P
Involuntary urine loss 44.1 43.8 .89
Use of pads for urine loss during day
and night
20.5 16.2 .05
Use of nappies for urine loss 4.2 4.7 .36
Stress incontinence 24.0 32.4 .05
Urge incontinence 27.9 26.9 .82
Combination of stress and urge
incontinence
21.1 21.4 .94
Strong urge for defecation 78.7 60.9 .002
Defecation within 1 h of the last bowel
opening
92.0 82.5 <.001
Anal mucus loss 29.9 14.4 .01
Pads for faecal leakage 57.7 34.4 .005
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total
mesorectal excision.
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capacity for the neorectum to act as a reservoir and con-
sequently leads to more frequent defecation within 1 h
and a higher stool frequency.
In this study, irradiated men reported to have more
erection diﬃculties compared with non-irradiated men
at 14 years after treatment, which conﬁrms the previous
analysis of this trial [23]. Sexual function of rectal cancer
survivors was also assessed in a study of the NorwegianRectal Cancer Registry (NRCR). Patients were included
if they had been treated with pre- or postoperative
(chemo-) radiation or with surgery only, and at 5 years
after treatment a higher prevalence of erectile dysfunc-
tion after radiation was found (86% in irradiated males
versus 55% in non-irradiated males) [8]. With regard to
females in the NRCR study, more vaginal dryness (50%
after radiation versus 24% after surgery only), dyspareu-
nia (35% versus 11%) and reduced vaginal dimension
(35% versus 6%) were found after radiotherapy [7]. In
the previous analysis of the TME trial 2 years after
treatment, females reported problems with lubrication
and dyspareunia after PRT + TME as well [23]. How-
ever, 14 years after treatment, no diﬀerence in vaginal
dryness was found between the treatment arms. When
comparing patients treated for rectal cancer with the
Dutch population, all treated males reported less inter-
est in sex, less sexual activity, decreased extent to which
sex was enjoyable and more erection diﬃculties. Treated
females also reported a decreased extent to which sex
was enjoyable. Furthermore, irradiated females reported
more vaginal dryness, and more pain at intercourse
compared with the Dutch population. In the study using
data from the Eindhoven Cancer registry, sexual func-
tion of patients 4 years after treatment was compared
with the Dutch population. This study found results
pointing in the same direction, but did ﬁnd a diﬀerence
in female sexual function and no diﬀerence in sexual
enjoyment of males. However, no surgery only group
was included in this analysis [25].
Despite the increased bowel symptoms and erection
diﬃculties in male patients in the irradiated group,
scores for general health status and functioning scales
were not diﬀerent from the non-irradiated group. This
was also found in two other studies in, which patients
were treated with surgery alone or with additional
PRT [11,12]. When HRQL is compared between
PRT + TME patients and patients who received preop-
erative (Polish trial) [26], or postoperative chemoradia-
tion (MRC CR07/NCIC CTG C016) [27], no
diﬀerences were reported either. In addition, previous
analysis of the TME trial did not ﬁnd diﬀerences in over-
all functioning and general health status between the
treatment arms [23]. Possible explanations for why
bowel and sexual dysfunction after PRT did not impact
on general health status and functioning scores com-
pared with TME are: ﬁrstly, patients adapt to their
symptoms, especially 14 years after treatment; secondly,
the impact of the symptoms is too small to have an eﬀect
on the more general functioning scales of the QLQ-C30.
In the Stockholm trials, more urinary incontinence
was demonstrated in the PRT + surgery group [12], a
ﬁnding that was not observed in our study. Because
the Stockholm trials included a higher proportion of
females (46.0%) compared to our study (41.2%), an
additional analysis was performed in female patients,
Table 5
Sexual items of EORTC QLQ-CR38, EORTC QLQ CX24 and EORTC QLQ-PR25.
Mean score
PRT + TME
Mean score
TME
P* D
PRT + TME  Norm
P D
TME  Norm
P
Male
Sexual interest 27.8 30.9 .27 14.7 <.001 12.9 <.001
Sexual activity 17.6 23.4 .04 11.3 <.001 6.6 .01
To what extent was sex enjoyable 54.8 53.1 .61 8.7 .001 10.8 <.001
Erection diﬃculties 72.4 55.7 .001 38.7 <.001 24.3 <.001
Ejaculation problems 59.4 48.6 .07
Uncomfortable about being sexually
intimate
44.6 31.5 .03
Female
Sexual interest 15.9 19.7 .59. 3.5 .19 0.1 .68
Sexual activity 16.7 19.3 76 1.6 .92 3.7 .48
To what extent was sex enjoyable 31.6 44.7 .08 22.1 <.001 9 .006
Vaginal dryness 35.8 24.2 .15 18.3 <.001 3.7 .08
Pain during intercourse 24.1 9.9 .04 20.8 <.001 3.4 .19
Vagina felt short/tight 25.6 15.4 .17
Abbreviations: PRT, preoperative short-term radiotherapy; TME, total mesorectal excision; Norm, age and gender matched Dutch population.
Higher scores for functioning indicate better functioning. For the symptom items, a higher score reﬂects a higher level of symptoms and decreased
HRQL. A negative diﬀerence in functioning indicates worse functioning in the treatment arms and a positive diﬀerence for symptoms indicates a
higher level of symptoms in the treatment arms compared to Norm.
* Diﬀerence between PRT + TME and TME.
 Diﬀerence between Norm and PRT + TME.
 Diﬀerence between Norm and TME.
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PRT + TME and TME. In the Stockholm trials,
32.4% of the patients were originally included in the
Stockholm I trial. In this trial patients received preoper-
ative radiotherapy (5  5 Gy) using a two-ﬁeld tech-
nique. With this technique a larger part of the bladder
is included in the radiation ﬁeld compared to patients
irradiated with a three or four-ﬁeld technique. Other
large randomised studies, which used the three or
four-ﬁeld technique, did not ﬁnd major eﬀects on the
urinary function either [6,10].
As mentioned above, radiation technique is relevant
for the risk of treatment-related toxicity. When irradi-
ated volumes are reduced, adverse eﬀects reduce as well,
as can be seen when the TME trial is compared with
the Stockholm I trial [28]. With the introduction of
3D-conformal radiotherapy and intensity-modulated
radiotherapy, damage to adjacent healthy tissue can be
minimised, which results in less acute bowel toxicity [29].
Although likely, it is not yet clear if these new radiation
techniques also decrease long-term treatment-related
toxicity. Therefore, optimal patient selection for radio-
therapy is required, ensuring that only patients who
are most likely to beneﬁt from radiotherapy should
receive this treatment. In addition, a recent trial found
that bowel function could be improved with an interven-
tion by a gastroenterologist or nurse during follow-up,
compared to a self-help booklet [30]. This result shows
that in the follow-up of patients treated for rectal cancer
speciﬁc attention should be paid to functional outcome.
This very long-term HRQL analysis shows that
14 years after treatment for resectable rectal cancer,
patients still experience negative eﬀects of theirtreatment. PRT + TME patients without stoma
reported more bowel dysfunction than TME patients,
and both treatment groups reported more sexual dys-
function than the norm population. Finally, both treat-
ment arms showed a clinically small decrease in overall
functioning and global health status compared to the
norm population. These ﬁndings can be used to provide
newly diagnosed rectal cancer patients with information
about their possible long-term morbidity and health sta-
tus after PRT + TME in order to make an informed
decision about the risks and beneﬁts of adjuvant
radiotherapy.Conﬂict of interest statement
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